Small molecule inhibitors of cyclic di-AMP signaling

Simple item page
dc.contributor.advisorSINTIM, HERMAN Oen_US
dc.contributor.advisorJULIN, DOUGLASen_US
dc.contributor.authorOPOKU-TEMENG, CLEMENTen_US
dc.contributor.departmentBiochemistryen_US
dc.contributor.publisherDigital Repository at the University of Marylanden_US
dc.contributor.publisherUniversity of Maryland (College Park, Md.)en_US
dc.date.accessioned2019-02-08T06:31:20Z
dc.date.available2019-02-08T06:31:20Z
dc.date.issued2018en_US
dc.description.abstractGlobally, it is estimated that more than 700,000 people die annually from infections caused by drug-resistant bacterial pathogens. Resistant strains of bacteria continue to be isolated in healthcare and community settings. At the same time, the antibiotic pipeline remains dry – exemplified by the paucity of new antibiotics introduced into clinical use. Consequently, antibiotic-resistant strains are rapidly spreading, and antibiotic-resistant infections persist. Additionally, the existing antibiotics target one of the common targets – DNA, RNA, protein and cell wall synthesis. There is an apparent need to identify antibacterial agents against novel targets to slow down the generation of resistance. Cyclic dinucleotides have emerged as central regulators of bacterial physiology. Particularly, cyclic di-AMP (c-di-AMP) regulates cell wall homeostasis, cell size, potassium ion transport, virulence and biofilm formation in various Gram-positive pathogens including Staphylococcus aureus, Enterococcus faecalis, Listeria monocytogenes and Streptococcus pneumoniae. It has been demonstrated that under standard laboratory conditions, deletion of the diadenylate cyclase genes that encode c-di-AMP synthesizing enzymes (diadenylate cyclase, DAC) was lethal in human pathogens like S. aureus and L. monocytogenes. Hence, DACs have been suggested as potential antibiotic targets. Thus far, the effect of c-di-AMP on bacterial physiology has been studied using genetic approaches whereby the key players of the second messenger signaling are deleted, inactivated or overexpressed to create conditions of varying intracellular c-di-AMP levels. However, these approaches are not amenable to drug development. Cell permeable small molecule modulator or c-di-AMP levels are required to validate the druggability of c-di-AMP signaling. This dissertation reports the identification of different small molecules that potently inhibit c-di-AMP synthesis. The cell permeable inhibitors possess the ability to decrease the intracellular concentration of c-di-AMP. Furthermore, the antibacterial activities of the cell permeable c-di-AMP synthesis inhibitors have been characterized. Efforts towards the development of antibiotics have also been discussed.en_US
dc.identifierhttps://doi.org/10.13016/fgha-r3rs
dc.identifier.urihttp://hdl.handle.net/1903/21740
dc.language.isoenen_US
dc.subject.pqcontrolledBiochemistryen_US
dc.subject.pquncontrolledagr systemen_US
dc.subject.pquncontrolledAntibiotic resistanceen_US
dc.subject.pquncontrolledCyclic di-AMP signalingen_US
dc.subject.pquncontrolledDiadenylate cyclase inhibitorsen_US
dc.subject.pquncontrolledGlobal proteomicsen_US
dc.subject.pquncontrolledSynergyen_US
dc.titleSmall molecule inhibitors of cyclic di-AMP signalingen_US
dc.typeDissertationen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
OPOKUTEMENG_umd_0117E_19553.pdf
Size:
3.88 MB
Format:
Adobe Portable Document Format
Download
(RESTRICTED ACCESS)

Collections

UMD Theses and Dissertations
Chemistry & Biochemistry Theses and Dissertations